Neurogen Corporation (NRGN) Announces Third Quarter 2009 Financial Results and Updates Operations  
11/6/2009 10:05:28 AM

BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (NASDAQ: NRGN), a drug development company historically focused on drugs for psychiatric and neurological disorders, today announced financial and operating results for the quarter ended September 30, 2009. The Company also announced its analysis of results from a previously suspended Phase 2 study of aplindore in Restless Legs Syndrome (RLS) and that it has entered into an agreement to sell all real estate owned by the Company.